Aim immunotech announces central irb approval of phase 2 study protocol evaluating ampligen® for the treatment of post-covid conditions

Preliminary data of ampligen seen to date demonstrates potential to be an effective treatment option for post-covid conditions preliminary data of ampligen seen to date demonstrates potential to be an effective treatment option for post-covid conditions
AIM Ratings Summary
AIM Quant Ranking